Mighty Therapeutics

Mighty Therapeutics is a private, commercial-stage biotechnology company focused on therapies for rare and age-related diseases driven by mitochondrial dysfunction. The company rebranded from Stealth BioTherapeutics in June 2026 following the U.S. approval and launch of Forzinity, an elamipretide injection for Barth syndrome. Mighty is building the field of mitochondrial medicine around therapies that directly target mitochondrial dysfunction, with late-stage development programs in dry age-related macular degeneration and polymerase gamma-related mitochondrial disease and earlier pipeline work in Parkinson's disease and long-chain fatty acid disorders. The company is headquartered in Needham, Massachusetts and is backed by investors including Morningside, with additional debt financing from K2 HealthVentures. Its strategy combines commercialization of its first approved product with continued expansion of a broader pipeline targeting mitochondrial bioenergetics.